Tobacco Prevention & Cessation最新文献

{"title":"Nicotine metabolite ratio and attitude towards nicotine metabolite ratio informed smoking cessation care in Jordan.","authors":"Ahmed Salem, Fanar Alsmarat, Tasneem Al-Awaida, Layth Al-Ramahi, Yousef Shawawrah","doi":"10.18332/tpc/217141","DOIUrl":"10.18332/tpc/217141","url":null,"abstract":"<p><strong>Introduction: </strong>Jordan has one of the highest global smoking and secondhand smoke (SHS) exposure rates. Nicotine metabolite ratio (NMR), the ratio of nicotine metabolites trans-3'-hydroxycotinine to cotinine, serves as a marker for tailored smoking cessation strategies to improve abstinence rates. This study examined smokers' NMR status, attitudes toward NMR-informed smoking cessation care, and SHS exposure markers in non-smokers exposed and not exposed to SHS.</p><p><strong>Methods: </strong>This cross-sectional study recruited participants using convenience sampling from Amman and Madaba, Jordan. Participants were categorized into current smokers, non-smokers not exposed to SHS, and non-smokers exposed to SHS. Smokers were classified as slow (NMR <0.31) or fast (NMR ≥0.31) metabolizers. A baseline questionnaire gathered demographics, smoking data, and attitudes toward NMR-informed smoking cessation care. Statistical analyses, including descriptive statistics, chi-squared tests, and non-parametric tests were performed.</p><p><strong>Results: </strong>A total of 251 participants were recruited: 125 smokers (49.8%), 63 non-smokers exposed to SHS (25.1%), and 63 non-smokers not exposed to SHS (25.1%). Median cotinine levels were high in non-smokers exposed to SHS (36.1 ng/mL) and non-smokers not exposed to SHS (32 ng/mL). Among smokers, 105 (84%) were fast nicotine metabolizers (NMR ≥0.31) and 20 (16%) were slow metabolizers (NMR <0.31), with a median NMR of 0.52 (range: 0.14-6.6). Most smokers showed a positive attitude towards NMR-informed smoking cessation care.</p><p><strong>Conclusions: </strong>The predominance of fast nicotine metabolizers in this study underscores the need for NMR-tailored cessation approaches. High SHS exposure observed underscores the need to enforce strict public smoking restrictions in Jordan.</p>","PeriodicalId":44546,"journal":{"name":"Tobacco Prevention & Cessation","volume":"12 ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13069928/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147677294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The use of interactive and engaging events in Austin, Texas, to promote the US return of IQOS.","authors":"Josephine T Hinds, Eugene M Talbot, Ollie Ganz, Cristine D Delnevo","doi":"10.18332/tpc/214726","DOIUrl":"10.18332/tpc/214726","url":null,"abstract":"<p><p>IQOS is a heated tobacco product from Philip Morris International (PMI) with modified risk tobacco product (MRTP) designation from the U.S. Food and Drug Administration (FDA). The commercial relaunch of IQOS featured experiential marketing centered in Austin, Texas, and began in October 2024. Invitation-only events were offered to adults aged ≥21 years who resided near Austin/Travis County and confirmed they were tobacco users when they joined the 'IQOS Circle'. Events were free-of-charge and included live music concerts, movie premieres, and seasonally and locally themed parties. Events offered free food, drinks, and giveaways, and usually included PMI representatives who invited discussion and questions about IQOS, where customers could hold devices with the promise that opportunities to try IQOS were coming soon. A two-day downtown block party marked IQOS' commercial release in March 2025, offering 'guided experiences' to customers who could then initiate a 14-day trial. The IQOS device and charging case with ten packs of HEETS sticks cost $1.00, plus a non-refundable $40 'trial fee'. Within the trial window, customers could return the product free of charge or pay an additional $60.00 to keep the device. In April 2025, IQOS products were made available for purchase online to Austin-area zip codes, and on 2 September 2025, shipping expanded to 'selected major cities' in Texas, including Dallas, Houston, and San Antonio. Events in Austin, TX and subsequent pilots in Ft. Lauderdale, FL, and Jackson, MS will inform PMI's launch of ILUMA, their most advanced IQOS model currently awaiting FDA authorization. It remains to be seen whether IQOS will provide health benefits to individuals who switch completely to IQOS from cigarettes, or whether those initiating IQOS are cigarette-naïve and/or otherwise not using nicotine products. Continued monitoring of the use and appeal of IQOS will be essential to tobacco control and public health efforts.</p>","PeriodicalId":44546,"journal":{"name":"Tobacco Prevention & Cessation","volume":"12 ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13044814/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147624014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends and burden of tobacco use in Nepal: Insights from the Global Burden of Disease study 1990-2021.","authors":"Kiran Paudel, Kamal Gautam, Sandhya Niroula, Sandesh Bhusal, Jeffrey A Wickersham, Safaet Hossain Sujan, Bhakta Kc, Tara B Adhikari, Roman Shrestha","doi":"10.18332/tpc217390","DOIUrl":"10.18332/tpc217390","url":null,"abstract":"<p><strong>Introduction: </strong>Tobacco consumption is a significant public health problem in Nepal, accounting for 39200 deaths each year, accounting for 23.7% of all deaths. While Nepal has taken several policy measures to strengthen tobacco control, the persistent burden of tobacco and the associated health risks highlight the need for continuous monitoring and evaluation. Therefore, this study assessed the trend in age-specific and sex-specific mortality and disability attributable to different forms of tobacco use (smoking, chewing tobacco) in Nepal from 1990 to 2021.</p><p><strong>Methods: </strong>This observational study used publicly available data from Nepal's Global Burden of Disease (GBD) 2021 estimations. The age-standardized and age-specific summary exposure value (SEV), mortality, and disability-adjusted life years (DALYs) were extracted to measure the burden and trend of tobacco use. The data are presented as percentages or rates per 100000 population.</p><p><strong>Results: </strong>From 1991 to 2021, the age-standardized SEV of tobacco consumption for both sexes at all ages decreased from 44.1% to 28.2%. The age-standardized deaths attributable to tobacco use, including all forms of tobacco products, decreased by (46.7%) from 262.9 (95% UI: 193.5-344.3) per 100000 in 1990 to 140.2 (95% UI: 101.1-181.9) per 100000 in 2021.</p><p><strong>Conclusions: </strong>Despite declines in SEV, and DALYs from 1990 to 2021, tobacco use remains a major public health concern. Strengthening smoking cessation programs, enforcing stricter tobacco control policies, raising taxes on tobacco products, and expanding public awareness campaigns are essential to reducing its burden.</p>","PeriodicalId":44546,"journal":{"name":"Tobacco Prevention & Cessation","volume":"12 ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13001751/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147500118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical and psychosocial factors predicting persistent smoking in hospitalized patients with atherosclerotic vascular disease: A prespecified analysis of two randomized controlled trials.","authors":"Vilde Getz, Karin Pleym, Toril Dammen, Einar Husebye, Elise Sverre, Costas Papageorgiou, Harald Weedon-Fekjær, John Munkhaugen","doi":"10.18332/tpc/217328","DOIUrl":"10.18332/tpc/217328","url":null,"abstract":"<p><strong>Introduction: </strong>Smoking remains prevalent after hospitalization for atherosclerotic vascular disease, even with cessation programs. Understanding the clinical and psychosocial factors influencing long-term abstinence is essential for identifying patients who may benefit from tailored interventions. This study aimed to identify clinical and psychosocial factors associated with sustained smoking cessation in patients with atherosclerotic disease who were admitted to hospital for an elective or unplanned vascular event and enrolled in a cessation intervention study.</p><p><strong>Methods: </strong>This is a prespecified analysis of two randomized intervention trials that recruited participants from three secondary care hospitals in Norway between 2021 and 2023. Patients who smoked at least one cigarette daily before admission were randomized to: 1) motivational counselling and proactive referral to municipal cessation services (intervention); or 2) brief advice and contact information (control). Data were collected from medical records, a questionnaire, and telephone interviews. Logistic regression analyses were used to identify the prespecified factors associated with smoking status at 12 months.</p><p><strong>Results: </strong>In the total study population (n=262), 34% (n=88) reported 12-month sustained smoking abstinence. Anxiety diagnosis (adjusted odds ratio, AOR=4.2), shorter sleep duration per hour (AOR=1.3), living alone (AOR=2.2), somatic comorbidity per point on the Charlson score (AOR=1.5), and being in the precontemplation stage (AOR=2.9) were associated with persistent smoking. Increasing motivation per point on a 0-10 Likert scale (AOR=0.7), being in the preparation stage (AOR=0.4), and myocardial infarction or stroke as the index diagnosis (AOR=0.5) were associated with smoking abstinence. Results were generally consistent across intervention allocation groups.</p><p><strong>Conclusions: </strong>Motivation and readiness for smoking cessation were key predictors of abstinence. Living alone, anxiety disorders, and shorter sleep duration were associated with persistent smoking. These factors may help identify subgroups who could benefit from more targeted support.</p><p><strong>Clinical trial registration: </strong>The study is registered on the official website of ClinicalTrials.gov.</p><p><strong>Identifiers: </strong>NCT04772144 and NCT05049174.</p>","PeriodicalId":44546,"journal":{"name":"Tobacco Prevention & Cessation","volume":"12 ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13001752/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147500131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Racism, discrimination, and distress: A cross-sectional examination of smoking behaviors among adults who smoke during the COVID-19 pandemic.","authors":"Robert T Fairman, Dennis E Reidy, Lucy Popova, Claire A Spears","doi":"10.18332/tpc/215707","DOIUrl":"10.18332/tpc/215707","url":null,"abstract":"<p><strong>Introduction: </strong>Racial and ethnic disparities in tobacco use and related health consequences persist. Experiences with racial discrimination have been associated with higher likelihood of smoking and worse cessation outcomes. The purpose of this study is to examine associations between perceived discrimination with serious quit attempts, smoking relapse, and changes in motivation to quit smoking, during the COVID-19 pandemic.</p><p><strong>Methods: </strong>Data came from an October-November 2020 US nationally representative cross-sectional survey of adults who currently smoked cigarettes (n=1223). Participants reported changes in smoking frequency, motivation to quit, quit attempts, and relapse since February 2020. Perceived discrimination was assessed using a modified Everyday Discrimination Scale, the Complementary and Integrative Research Lab Pandemic Impact Questionnaire, and Domain-Specific Stress Scales. In addition to the associations between discrimination and smoking behaviors, we explored differences in smoking behaviors by race.</p><p><strong>Results: </strong>Approximately 13-25% of participants reported having relapsed to smoking since the beginning of the COVID-19 pandemic. Black participants perceived higher levels of everyday discrimination and were more likely to report having been avoided or insulted because of their race or ethnicity. Participants who experienced racism and discrimination were more likely to have made a serious attempt to quit smoking since the beginning of COVID-19 (AOR=1.80; 95% CI: 1.08-3.03). Experiences with police brutality (AOR=1.61; 95% CI: 1.31-1.97), as well as being avoided or insulted because of their race or ethnicity (AOR=4.70; 95% CI: 2.75-8.04) was associated with higher likelihood of relapse.</p><p><strong>Conclusions: </strong>Perceived experiences with racism and discrimination among people who smoke were associated with making a serious smoking quit attempt but also predicted relapse. Further research can develop smoking cessation interventions that consider various social stressors, such as experiences with racism and discrimination.</p>","PeriodicalId":44546,"journal":{"name":"Tobacco Prevention & Cessation","volume":"12 ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13001748/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147500066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute respiratory and ocular effects of electronic cigarettes: A pre-post experimental study in healthy users.","authors":"Mercedes Segura Romero, Ignacio Garcia-Basterra, Sara Sánchez Martin, Jose Carlos Calero Valera, Alvaro Martinez Mesa, Javier Lopez Garcia, Miguel Benítez Cano-Gamonoso, Isabel Asschert Agüero, Jose Luis Velasco-Garrido, Eva Cabrera Cesar","doi":"10.18332/tpc/216112","DOIUrl":"10.18332/tpc/216112","url":null,"abstract":"<p><strong>Introduction: </strong>The use of electronic cigarettes (ECs) has increased alarmingly among young people, often perceived as a safer alternative to conventional tobacco. Studies demonstrating that these are not harmless products are essential to raise awareness of their potential health risks.</p><p><strong>Methods: </strong>A pre-post exposure experimental study was conducted between March and June 2024 at Virgen de la Victoria University Hospital, Málaga, Spain, in 40 healthy regular EC users aged ≥18 years. Respiratory parameters (FeNO, spirometry, oscillometry) and ophthalmological assessments (Schirmer test, Optical Coherence Tomography, and Pentacam) were evaluated before and after acute EC exposure (40-60 inhalations).</p><p><strong>Results: </strong>Following acute exposure, a statistically significant decrease in FeNO was observed from 21.88 ± 22.01 to 18.05 ± 18.08 ppb (p=0.019), particularly in non-smokers (p=0.003), suggesting an airway inflammatory response. In dual users, a significant increase in pulmonary resistance from 0.21 ± 0.36 to 0.35 ± 0.48 kPa/L∙s (p=0.028) was detected. At the ocular level, the Schirmer test showed reduced tear secretion in 47.5% of participants. Additionally, significant changes were found in macular flow density (p=0.024) and inferior macular choroidal thickness (p=0.015), suggesting a possible retinal hemodynamic alteration.</p><p><strong>Conclusions: </strong>Acute use of ECs induces measurable changes in both respiratory function and ocular parameters. These findings underscore the need to raise awareness about the potential adverse effects of vaping and highlight the importance of further research into its long-term consequences.</p>","PeriodicalId":44546,"journal":{"name":"Tobacco Prevention & Cessation","volume":"12 ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12976782/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147445499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of nurse-run smoking cessation discussions lasting up to 90 minutes: A systematic review and meta-analysis.","authors":"Klas Winell, Juha E Ahonen","doi":"10.18332/tpc/215042","DOIUrl":"10.18332/tpc/215042","url":null,"abstract":"<p><strong>Introduction: </strong>It is important that nurses are active in smoking cessation. We studied if cessation discussions by nurses, lasting up to 90 minutes, lead to cessation of smoking.</p><p><strong>Methods: </strong>A literature search was made from The Cochrane Central Register of Controlled Trials and MEDLINE. Randomized controlled trials on smoking cessation of adult daily smokers by nurses published from January 1983 to December 2023 were searched with the following defining of intervention: at least once face-to-face contact, a maximum of five contacts, total counselling time of ≤90 minutes, no concurrent cessation medication or physician input. Controls had no nurse counselling. The restricted maximum-likelihood method was used to calculate the odds ratio (OR) without adjustment for individual trials and to estimate the pooled effect. RoB 2 tool was used to assess the bias.</p><p><strong>Results: </strong>Seven studies involving 4443 smokers were included. All studies presented some risk of bias, and three were judged to have high overall risk of bias. The pooled analyses favored the controls but without a statistically significant effect at 12 months, biochemically validated abstinence (4295 smokers, six studies, OR=1.22; 95% CI: 0.83-1.80) and self-reported abstinence (3396 smokers, five studies, OR=1.02; 95% CI: 0.65-1.61). Substantial heterogeneity was observed (I²=57% for biochemically validated outcomes; I²=73% for self-reported outcomes).</p><p><strong>Conclusions: </strong>Our results of studies on nurse-run counselling lasting ≤90 minutes did not demonstrate effectiveness in promoting smoking cessation. This should be considered while organizing cessation care. Instead, smokers who are interested in using cessation medication should be given more time and offered the possibility to participate in cessation group counselling. Given that many participants in the included studies had long smoking histories and smoking-related illnesses, future RCTs should examine nurse-run cessation interventions in populations with shorter smoking histories and fewer comorbidities.</p>","PeriodicalId":44546,"journal":{"name":"Tobacco Prevention & Cessation","volume":"12 ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12941095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147327625","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Carbonyl emissions from heated tobacco products.","authors":"Efthimios Zervas, Niki Matsouki, Charikleia Tsipa, Zoe Gareiou","doi":"10.18332/tpc/214783","DOIUrl":"10.18332/tpc/214783","url":null,"abstract":"<p><strong>Introduction: </strong>The scope of this work is to determine the carbonyl emissions from five heated tobacco products (HTPs) and the existence of differences in the emissions based on the brand, on the stick (having a different flavor) and on the puffing regime.</p><p><strong>Methods: </strong>Carbonyls were determined in the mainstream emissions of HTPs. Vapors from 5 commercial HTPs: IQOS, LIL, PULZE, ILUMA and GLO, and fifteen different stick flavors were generated using a peristaltic pump under both ISO and Canadian puffing regimes. Carbonyls were collected in an impinger containing a 2,4-dinitrophenylhydrazine (2,4-DNPH) solution and analyzed using HPLC-UV.</p><p><strong>Results: </strong>All HTPs emit carbonyls. Acetaldehyde, propionaldehyde and butyraldehyde are detected in quantities varying from 34.35 to 72.11 μg/stick, 3.28 to 8.58 μg/stick and 3.07 to 6.20 μg/stick respectively, for the different brands and stick flavors. Formaldehyde and crotonaldehyde are found below the detection limit of the analytical method. Acetone and acrolein co-eluted and cannot be quantified. Under ISO regime, ILUMA emits more acetaldehyde than GLO, more propionaldehyde compared to the other brands and more butyraldehyde compared to PULZE, LIL and GLO. Under Canadian regime, no significant variations were found between the brands, except IQOS that emits more acetaldehyde than GLO. Also, the difference of the sticks, thus having a different flavor, within the same brand, has an impact on the emissions.</p><p><strong>Conclusions: </strong>Although HTPs are promoted as products with reduced risk compared to conventional cigarettes, still the detection of carbonyls in HTPs emissions is a fact and needs further research. All five HTPs used here and all sticks used emit carbonyls. Carbonyls' concentrations are found to vary significantly among the different brands, the difference of the sticks, and concerning flavor, and to increase when changing to a more intense puffing regime.</p>","PeriodicalId":44546,"journal":{"name":"Tobacco Prevention & Cessation","volume":"12 ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2026-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12914568/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146228988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expanding the evidence base: The impact of Tobacco 21 policies on youth tobacco use.","authors":"Danyi Li, Linyun Fu, Nathan Davies, Steve Sussman, Mary A Pentz","doi":"10.18332/tpc/214471","DOIUrl":"10.18332/tpc/214471","url":null,"abstract":"","PeriodicalId":44546,"journal":{"name":"Tobacco Prevention & Cessation","volume":"12 ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12897512/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146203274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Smokeless tobacco pack-years: Non-reporting in tobacco research.","authors":"Saravanan Sampoornam Pape Reddy, Delfin Lovelina Francis, Manish Rathi, Sukhbir Singh Chopra","doi":"10.18332/tpc/215589","DOIUrl":"10.18332/tpc/215589","url":null,"abstract":"","PeriodicalId":44546,"journal":{"name":"Tobacco Prevention & Cessation","volume":"12 ","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12897511/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146203257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}